JP2019536429A - ポリオーマウイルスのための免疫療法 - Google Patents

ポリオーマウイルスのための免疫療法 Download PDF

Info

Publication number
JP2019536429A
JP2019536429A JP2019514037A JP2019514037A JP2019536429A JP 2019536429 A JP2019536429 A JP 2019536429A JP 2019514037 A JP2019514037 A JP 2019514037A JP 2019514037 A JP2019514037 A JP 2019514037A JP 2019536429 A JP2019536429 A JP 2019536429A
Authority
JP
Japan
Prior art keywords
epitopes
epitope
virus
polyomavirus
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019514037A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536429A5 (https=
Inventor
カンナ，ラジーブ
ロビン アンバラティンガル トーマス，ジョージ
ロビン アンバラティンガル トーマス，ジョージ
アフテーブ，ブレイク，トル
Original Assignee
アタラ バイオセラピューティクス，インコーポレーテッド
アタラ バイオセラピューティクス，インコーポレーテッド
ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ
ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アタラ バイオセラピューティクス，インコーポレーテッド, アタラ バイオセラピューティクス，インコーポレーテッド, ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ, ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ filed Critical アタラ バイオセラピューティクス，インコーポレーテッド
Publication of JP2019536429A publication Critical patent/JP2019536429A/ja
Publication of JP2019536429A5 publication Critical patent/JP2019536429A5/ja
Priority to JP2023000505A priority Critical patent/JP7821133B2/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
JP2019514037A 2016-09-09 2017-09-08 ポリオーマウイルスのための免疫療法 Pending JP2019536429A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023000505A JP7821133B2 (ja) 2016-09-09 2023-01-05 ポリオーマウイルスのための免疫療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662385456P 2016-09-09 2016-09-09
US62/385,456 2016-09-09
PCT/US2017/050686 WO2018049165A1 (en) 2016-09-09 2017-09-08 Immunotherapy for polyomaviruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023000505A Division JP7821133B2 (ja) 2016-09-09 2023-01-05 ポリオーマウイルスのための免疫療法

Publications (2)

Publication Number Publication Date
JP2019536429A true JP2019536429A (ja) 2019-12-19
JP2019536429A5 JP2019536429A5 (https=) 2020-10-22

Family

ID=61562223

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019514037A Pending JP2019536429A (ja) 2016-09-09 2017-09-08 ポリオーマウイルスのための免疫療法
JP2023000505A Active JP7821133B2 (ja) 2016-09-09 2023-01-05 ポリオーマウイルスのための免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023000505A Active JP7821133B2 (ja) 2016-09-09 2023-01-05 ポリオーマウイルスのための免疫療法

Country Status (14)

Country Link
US (1) US20200197439A1 (https=)
EP (1) EP3509632A4 (https=)
JP (2) JP2019536429A (https=)
KR (2) KR102698554B1 (https=)
CN (1) CN109922830A (https=)
AU (2) AU2017322397A1 (https=)
BR (1) BR112019004102A2 (https=)
CA (1) CA3035906A1 (https=)
IL (1) IL265103B2 (https=)
MX (1) MX2019002566A (https=)
PH (1) PH12019500344A1 (https=)
RU (1) RU2019110269A (https=)
SG (1) SG11201901166QA (https=)
WO (1) WO2018049165A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210301255A1 (en) 2018-09-10 2021-09-30 Atara Biotherapeutics, Inc. Methods for expanding antigen-specific car-t cells, compositions and uses related thereto
WO2021014213A1 (en) * 2019-07-24 2021-01-28 The Council Of The Queensland Institute Of Medical Research Immunotherapy for polyomaviruses
CN113278634B (zh) * 2020-11-16 2022-06-28 艾棣维欣(苏州)生物制药有限公司 一种预防和治疗默克尔细胞癌的新型疫苗

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008116468A2 (en) * 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105505870B (zh) * 2016-01-20 2017-07-25 深圳市中美康士生物科技有限公司 免疫细胞培养方法以及人工滋养细胞在免疫细胞培养中的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008116468A2 (en) * 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"large T [Human polyomavirus 1]", DATABASE GENBANK [ONLINE], JPN6021043840, 7 August 2007 (2007-08-07), pages 75325, ISSN: 0004635048 *
"small t [Human polyomavirus 1]", DATABASE GENBANK [ONLINE], JPN6021043841, 7 August 2007 (2007-08-07), pages 75326, ISSN: 0004635047 *
"VP1 [Human polyomavirus 1]", DATABASE GENBANK [ONLINE], JPN6021043839, 26 January 2006 (2006-01-26), pages 53654, ISSN: 0004635049 *
CYTOTHERAPY, vol. 16, JPN6021043837, 2014, pages 1325 - 1335, ISSN: 0004867258 *
HUMAN IMMUNOLOGY, vol. 70, JPN6021043838, 2009, pages 722 - 728, ISSN: 0004867257 *
JOURNAL OF GENERAL VIROLOGY, vol. 87, JPN6021043836, 2006, pages 2951 - 2960, ISSN: 0004635052 *
JOURNAL OF VIROLOGY, vol. 79, no. 17, JPN6021043834, 2005, pages 11170 - 11178, ISSN: 0004635054 *
VIROLOGY, vol. 350, JPN6021043835, 2006, pages 128 - 136, ISSN: 0004635053 *

Also Published As

Publication number Publication date
IL265103B2 (en) 2024-06-01
WO2018049165A1 (en) 2018-03-15
AU2017322397A1 (en) 2019-04-04
PH12019500344A1 (en) 2020-01-20
EP3509632A1 (en) 2019-07-17
EP3509632A4 (en) 2021-02-17
RU2019110269A3 (https=) 2020-12-03
KR20240133760A (ko) 2024-09-04
SG11201901166QA (en) 2019-03-28
JP2023040149A (ja) 2023-03-22
RU2019110269A (ru) 2020-10-09
AU2024264673A1 (en) 2024-12-05
US20200197439A1 (en) 2020-06-25
CA3035906A1 (en) 2018-03-15
MX2019002566A (es) 2019-12-05
IL265103A (https=) 2019-04-30
NZ751506A (en) 2023-09-29
JP7821133B2 (ja) 2026-02-26
BR112019004102A2 (pt) 2019-05-28
KR102698554B1 (ko) 2024-08-23
CN109922830A (zh) 2019-06-21
KR20190068529A (ko) 2019-06-18
IL265103B1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
ES2328945T3 (es) Epitopos inmunogenos de linfocitos t colaboradores de antigenos tumorales humanos y metodos inmunoterapeuticos utilizando dichos epitopos.
TWI752930B (zh) 抗原特異性ｔｃｒ的新生成
JP7821133B2 (ja) ポリオーマウイルスのための免疫療法
US20110097312A1 (en) Anti-cancer vaccines
WO2014004385A2 (en) Anti-cancer vaccines
JP7270382B2 (ja) 免疫療法の方法
JP2025160241A (ja) ポリオーマウイルスのための免疫療法
WO2008007711A1 (en) Sart3-derived peptide useful in cancer vaccine therapy for hla-a3 supertype allele-positive prostate cancer patient
JP5065273B2 (ja) Ｈｌａ−ａ２４分子結合性ｋｉｆ由来ペプチド
CA2536654A1 (en) Anti-cancer vaccines
EP2270144B1 (en) Partial peptide of survivin presented on mhc class ii molecule and use thereof
JP2019520840A (ja) マルチウイルス特異的ｔ細胞免疫療法
US20250057881A1 (en) Compositions and methods for use of recombinant t cell receptors against claudin 6
NL2034657B1 (en) RCN1-derived TEIPP neoantigens and uses thereof
JP6918333B2 (ja) 細胞性免疫に認識されるペプチド、及びそれを利用した医薬薬剤
WO2024194498A2 (en) Cross reactive microbial peptide cancer vaccine and t cell receptors reactive thereto
HK40005722A (en) Immunotherapy for polyomaviruses
CN120857941A (zh) 经验证的hpv16衍生的刺激肽
JP2021526826A (ja) ウイルス検出アッセイ

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20191030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220203

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220906

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20221228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230105

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230106

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230131

C27A Decision to dismiss

Free format text: JAPANESE INTERMEDIATE CODE: C2711

Effective date: 20230322

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20230411